|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 October 2000, Vol. 96, No. 8, pp. 2814-2821
IMMUNOBIOLOGY
Rapid reconstitution of Epstein-Barr virus-specific T
lymphocytes following allogeneic stem cell transplantation
Natalie A. Marshall,
John
Greg Howe,
Richard Formica,
Diane Krause,
John E. Wagner,
Nancy Berliner,
Jill Crouch,
Ingrid Pilip,
Dennis Cooper,
Bruce R. Blazar,
Stuart Seropian, and
Eric G. Pamer
From the Sections of Infectious Diseases, Medical
Oncology, Hematology, and Nephrology and the Departments of Medicine,
Immunobiology, and Laboratory Medicine, Yale School of Medicine, New
Haven, CT; and the University of Minnesota Cancer Center, the
Department of Pediatrics, and the Division of Blood and Marrow
Transplantation, Minneapolis, MN.
Epstein-Barr virus (EBV)-specific CD8 T lymphocytes are present at
remarkably high frequencies in healthy EBV+
individuals and provide protection from EBV-associated
lymphoproliferative diseases. Allogeneic peripheral blood stem cell
transplantation (allo-PBSCT) is a commonly used therapy in which T-cell
surveillance for EBV is temporarily disrupted. Herein, human leukocyte
antigen (HLA) class I tetramers were used to investigate the
reestablishment of the EBV-specific CD8 T-cell repertoire in patients
following allo-PBSCT. CD8+ T cells specific for lytic and
latent cycle-derived EBV peptides rapidly repopulate the periphery of
matched sibling allo-PBSCT patients. The relative frequencies of T
cells specific for different EBV peptides in transplantation recipients
closely reflect those of their respective donors. Investigation of
patients at monthly intervals following unmanipulated allo-PBSCT
demonstrated that the frequency of EBV-specific T cells correlates with
the number of EBV genome copies in the peripheral blood and that
expansion of EBV-specific T-cell populations occurs even in the
setting of immunosuppressive therapy. In contrast, patients undergoing T-cell-depleted or unrelated cord blood transplantation have
undetectable EBV-specific T cells, even in the presence of Epstein-Barr
viremia. The protective shield provided by EBV-specific CD8 T cells is rapidly established following unmanipulated matched sibling allo-PBSCT and demonstrates that HLA class I tetramers complexed with viral peptides can provide direct and rapid assessment of pathogen-specific immunity in this and other vulnerable patient populations.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Trivedi, R. Y. Williams, R. J. O'Reilly, and G. Koehne
Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy
Blood,
April 1, 2005;
105(7):
2793 - 2801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Doubrovina, M. M. Doubrovin, S. Lee, J.-H. Shieh, G. Heller, E. Pamer, and R. J. O'Reilly
In vitro Stimulation with WT1 Peptide-Loaded Epstein-Barr Virus-Positive B Cells Elicits High Frequencies of WT1 Peptide-Specific T Cells with In vitro and In vivo Tumoricidal Activity
Clin. Cancer Res.,
November 1, 2004;
10(21):
7207 - 7219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Kang, T. Quan, H. Nolasco, S.-H. Park, M. S. Hong, J. Crouch, E. G. Pamer, J. G. Howe, and J. Craft
Defective Control of Latent Epstein-Barr Virus Infection in Systemic Lupus Erythematosus
J. Immunol.,
January 15, 2004;
172(2):
1287 - 1294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Meij, J. W. J. van Esser, H. G. M. Niesters, D. van Baarle, F. Miedema, N. Blake, A. B. Rickinson, I. Leiner, E. Pamer, B. Lowenberg, et al.
Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease
Blood,
June 1, 2003;
101(11):
4290 - 4297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kuzushima, N. Hayashi, A. Kudoh, Y. Akatsuka, K. Tsujimura, Y. Morishima, and T. Tsurumi
Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells
Blood,
February 15, 2003;
101(4):
1460 - 1468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chakrabarti, V. Mautner, H. Osman, K. E. Collingham, C. D. Fegan, P. E. Klapper, P. A. H. Moss, and D. W. Milligan
Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery
Blood,
August 13, 2002;
100(5):
1619 - 1627.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Koehne, K. M. Smith, T. L. Ferguson, R. Y. Williams, G. Heller, E. G. Pamer, B. Dupont, and R. J. O'Reilly
Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors
Blood,
March 1, 2002;
99(5):
1730 - 1740.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Thomas, A. Noble, E. Sawicka, P. W. Askenase, and D. M. Kemeny
CD8 T Cells Inhibit IgE Via Dendritic Cell IL-12 Induction That Promotes Th1 T Cell Counter-Regulation
J. Immunol.,
January 1, 2002;
168(1):
216 - 223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. J. van Esser, B. van der Holt, E. Meijer, H. G. M. Niesters, R. Trenschel, S. F. T. Thijsen, A. M. van Loon, F. Frassoni, A. Bacigalupo, U. W. Schaefer, et al.
Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT
Blood,
August 15, 2001;
98(4):
972 - 978.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
